Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Budesonide for COVID-19: real-time meta analysis of 8 studies
Covid Analysis, June 28, 2022, DRAFT
https://c19budesonide.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrish.. (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Ramakrish.. (RCT) 90% 0.10 [0.01-0.75] hosp./ER 1/70 10/69 Ramakrish.. (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 Ramlall (ICU) 71% 0.29 [0.11-0.78] death 33 (n) 915 (n) Intubated patients Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Yu (RCT) 6% 0.94 [0.44-1.98] ventilation 13/776 14/784 Yu (RCT) 52% 0.48 [0.23-1.01] ICU 10/771 21/779 Yu (RCT) 25% 0.75 [0.55-1.03] death/hosp. 72/787 116/1,069 Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Al Sulaiman (ICU) 32% 0.68 [0.41-1.13] death 30/64 31/64 ICU patients MP 80%​1 Al Sulaiman (ICU) 47% 0.53 [0.31-0.93] death 25/65 29/65 ICU patients MP 80%​1 Alsultan (RCT) -7% 1.07 [0.42-2.71] death 5/14 7/21 Agustí (RCT) -23% 1.23 [0.08-19.0] death 1/40 1/49 Agustí (RCT) 39% 0.61 [0.12-3.17] progression 2/40 4/49 Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Monserrat V.. (PSM) 49% 0.51 [0.28-0.90] death n/a n/a budesonide COVID-19 outcomes c19budesonide.com Jun 2022 1 MP: multiple medications, percentage budesonide shown Favors budesonide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit